trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['rux,(-crux),(-trux)', 'breast', 'trastuzumab deruxtecan', 'paradigm']
at the #aacr23 session on trastuzumab deruxtecan in breast cancer- redefining her2-positive status? read more about the emerging her2-low paradigm in #breastcancer in this commentary by &amp; 
Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Views/likes/RTs are my own. She/her